Double maintains 2 strategies that include BHVN - Biohaven Ltd.
Yahoo
The stocks endured multiple headwinds during the month, especially Biohaven, which had one of its drug candidates deliver underwhelming results in a recent study. Finally, the resignation of a key Federal Food and Drug Administration (FDA) regulator toward the end of the month cast a pall over the FDA approval process under the tenure of new Secretary of Health and Human Services, Robert F. Kennedy Jr.
Yahoo
American Century Companies has boosted its stake in Biohaven (BHVN) by 9.5% during Q4, ETF Daily News reports, citing a recent SEC filing. The firm owned 558,761 shares of Biohaven after purchasing an additional 48,286 shares during the period, the report notes. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on BHVN: Biohaven falls -10.9% Immunovant data positive for Bioha
Yahoo
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. “We are thrilled to welcome Michael to Avalo’s Bo
SeekingAlpha
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for more on REGN stock news.
Yahoo
We recently published a list of 12 Stocks with Heavy Insider Buying in 2025. In this article, we are going to take a look at where Biohaven Ltd. (NYSE:BHVN) stands against other stocks with heavy insider buying in 2025. Insider trading is often seen as an important indicator of management’s confidence in their company’s future. […]
Yahoo
Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $63 from $69 and keeps an Overweight rating on the shares. Biohaven reported Q4 earnings on March 3 and provided “mixed” data updates for BHV-1300 and BHV-7000, with the updates for BHV-1300 being positive, as it achieved sustained reductions in total IgG of up to 84%, while the BHV-7000 Phase 2 data was negative, as it failed to reach statistical significance from the comparator on the Young Mania Rating Scale in bipolar mania
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MITK | -0.10% | $376.43M | -40.10% | 0.00% |
HLN | 0.21% | $45.90B | +23.30% | 0.50% |
RPRX | 0.21% | $13.55B | +8.61% | 2.68% |
LNT | -0.27% | $16.55B | +30.41% | 2.98% |
VHC | 0.29% | $35.77M | +37.68% | 0.00% |
HEES | -0.40% | $3.51B | +50.35% | 1.17% |
BNED | 0.42% | $364.72M | -83.00% | 0.00% |
SJW | 0.42% | $1.81B | -1.37% | 2.91% |
SPTN | 0.46% | $694.88M | +5.27% | 4.21% |
HUSA | 0.47% | $11.76M | -47.55% | 0.00% |
FCN | -0.52% | $5.79B | -22.12% | 0.00% |
FE | -0.59% | $23.40B | +6.40% | 4.13% |
BGS | -0.61% | $532.60M | -39.26% | 11.28% |
HAIN | 0.63% | $365.50M | -42.23% | 0.00% |
PSQH | -0.67% | $93.55M | -56.05% | 0.00% |
WTRG | -0.69% | $10.85B | +9.33% | 3.12% |
STVN | 0.70% | $5.72B | -30.31% | 0.28% |
POST | -0.82% | $6.54B | +11.31% | 0.00% |
CQP | 0.85% | $32.91B | +35.41% | 5.06% |
O | -0.85% | $50.94B | +8.24% | 5.57% |
Current Value
$21.951 Year Return
Current Value
$21.951 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -25.11% | $23.50B | +25.53% | 1.05% |
LITB | -17.04% | $41.93M | -46.48% | 0.00% |
K | -12.99% | $28.46B | +45.70% | 2.75% |
GIS | -12.71% | $32.41B | -14.20% | 3.90% |
ED | -12.54% | $38.69B | +21.90% | 2.95% |
VZ | -12.35% | $188.34B | +4.44% | 5.84% |
CPB | -11.18% | $11.75B | -8.27% | 3.73% |
CL | -10.95% | $75.88B | +6.19% | 2.07% |
KHC | -9.19% | $36.01B | -19.37% | 5.15% |
KMB | -8.38% | $47.39B | +13.36% | 3.37% |
PEP | -8.10% | $204.52B | -12.12% | 3.52% |
AWK | -8.02% | $28.51B | +22.92% | 1.99% |
HSY | -7.91% | $33.21B | -15.87% | 3.33% |
JKHY | -7.83% | $13.42B | +8.13% | 1.20% |
CHD | -7.82% | $26.66B | +5.00% | 1.03% |
AEP | -7.78% | $57.54B | +27.77% | 3.31% |
MO | -7.75% | $96.57B | +35.61% | 6.83% |
CCEC | -7.54% | $1.17B | +17.80% | 2.99% |
CORT | -7.46% | $8.84B | +226.74% | 0.00% |
PG | -7.21% | $397.45B | +8.55% | 2.32% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
OCUL | 42.77% | $1.17B | -13.14% | 0.00% |
KRYS | 40.80% | $5.21B | +1.76% | 0.00% |
IOVA | 40.29% | $1.16B | -74.73% | 0.00% |
RXRX | 39.65% | $2.13B | -40.76% | 0.00% |
GTLS | 39.23% | $6.91B | -3.63% | 0.00% |
RCKT | 38.97% | $671.77M | -75.23% | 0.00% |
CYTK | 37.74% | $4.77B | -43.25% | 0.00% |
DNLI | 37.46% | $2.00B | -29.07% | 0.00% |
ELVN | 37.44% | $973.23M | +6.83% | 0.00% |
HXL | 37.43% | $4.51B | -20.93% | 1.20% |
URI | 37.40% | $42.22B | -8.49% | 1.14% |
BNT | 37.06% | $10.90B | +33.38% | 0.00% |
MGRC | 37.06% | $2.78B | -6.60% | 1.78% |
ABG | 37.03% | $4.53B | +2.28% | 0.00% |
ITT | 37.00% | $10.86B | +0.95% | 1.08% |
SYRE | 36.89% | $933.38M | -55.31% | 0.00% |
ACLX | 36.74% | $3.69B | +6.38% | 0.00% |
IDYA | 36.72% | $1.43B | -61.21% | 0.00% |
VTYX | 36.71% | $75.40M | -79.54% | 0.00% |
AN | 36.58% | $6.57B | +4.68% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBTG | -<0.01% | $1.82B | 0.07% |
VGLT | -0.01% | $10.02B | 0.03% |
SPTL | 0.03% | $11.79B | 0.03% |
TOTL | 0.07% | $3.51B | 0.55% |
VGSH | -0.11% | $22.52B | 0.03% |
FLGV | -0.16% | $959.69M | 0.09% |
TAXF | 0.20% | $517.32M | 0.29% |
USCI | 0.24% | $240.82M | 1.07% |
TLT | 0.27% | $51.94B | 0.15% |
GOVI | 0.32% | $1.07B | 0.15% |
SUB | 0.41% | $8.76B | 0.07% |
BILS | 0.43% | $3.67B | 0.1356% |
SCHQ | -0.43% | $950.81M | 0.03% |
SCHR | 0.48% | $10.47B | 0.03% |
EDV | -0.53% | $4.00B | 0.05% |
SPTI | 0.56% | $7.77B | 0.03% |
CGSM | -0.59% | $640.07M | 0.25% |
BAB | 0.60% | $977.85M | 0.28% |
DBA | -0.63% | $829.48M | 0.93% |
IBTF | 0.75% | $2.22B | 0.07% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 54.23% | $4.76B | 0.35% |
IWO | 48.67% | $10.72B | 0.24% |
PTH | 48.18% | $107.91M | 0.6% |
KJUL | 48.05% | $155.05M | 0.79% |
IWC | 47.79% | $797.08M | 0.6% |
VXF | 47.34% | $19.92B | 0.05% |
GNOM | 47.08% | $47.13M | 0.5% |
VBK | 46.93% | $17.32B | 0.07% |
VTWO | 46.92% | $10.92B | 0.07% |
IWM | 46.76% | $62.65B | 0.19% |
TMSL | 46.73% | $660.41M | 0.55% |
KJAN | 46.39% | $317.59M | 0.79% |
SCHA | 46.03% | $15.94B | 0.04% |
ARKG | 45.88% | $936.86M | 0.75% |
SMMD | 45.38% | $1.29B | 0.15% |
NUSC | 45.37% | $1.10B | 0.31% |
RYLD | 45.35% | $1.38B | 0.6% |
VB | 45.27% | $59.06B | 0.05% |
ESML | 45.25% | $1.76B | 0.17% |
KOMP | 45.09% | $1.95B | 0.2% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -36.94% | $416.76M | 1.43% |
TAIL | -30.47% | $87.65M | 0.59% |
VIXY | -30.36% | $195.31M | 0.85% |
CTA | -17.42% | $978.30M | 0.76% |
USDU | -14.59% | $206.96M | 0.5% |
UUP | -10.27% | $325.79M | 0.77% |
IBTP | -10.21% | $111.57M | 0.07% |
CCOR | -9.72% | $64.12M | 1.18% |
KMLM | -9.25% | $218.49M | 0.9% |
BUXX | -8.67% | $234.79M | 0.25% |
UNG | -7.24% | $397.59M | 1.06% |
TPMN | -6.39% | $33.32M | 0.65% |
IBD | -6.17% | $382.70M | 0.44% |
IVOL | -5.93% | $476.36M | 1.02% |
TBLL | -5.80% | $2.13B | 0.08% |
GOVZ | -5.38% | $296.64M | 0.1% |
SCHO | -4.34% | $10.65B | 0.03% |
TFLO | -4.31% | $6.75B | 0.15% |
AGZD | -4.06% | $134.05M | 0.23% |
IYK | -3.96% | $1.53B | 0.4% |